Genera Biosystems Ltd GBI  Product Pipeline Analysis, 2019 Update [Published by Global Data] Prices from USD $638
12:53 EST 22 Jan 2020 | BioPortfolio Reports
Summary
Genera Biosystems Ltd GBL is a multiplexed molecular diagnostic testing product developer. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is a molecular diagnostic test for the detection and genotyping of high risk and low risk types of human papillomavirus that cause cervical cancer or genital warts. GBL uses AmpaSand beads technology to create identifiable clusters of beads that can be distinguished in a conventional flow cytometer. The company provides products to detect influenzaA, influenzaB, influenza A H1N1, influenzaA H5N1, respiratory syncytial virus, human metapneumovirus, adenovirus, rhinovirus, bordetella pertussis, and chlamydophila pneumonia. It collaborates with pathology customers and IVD companies. GBL is headquartered in Melbourne, Victoria, Australia. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Genera Biosystems Ltd
The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research  Development strategies
Develop marketentry and market expansion strategies
Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Related Biotechnology, Pharmaceutical and Healthcare News

Genera Biosystems Ltd GBI  Product Pipeline Analysis 2019 Update Published by Global Data Prices from USD $638

02:26 EST 12 Nov 2018 | BioPortfolio Reports
Summary
Genera Biosystems Ltd GBL is a multiplexed molecular diagnostic testing product developer. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is a molecular diagnostic test for the detection and genotyping of high risk and low risk types of human papillomavirus that cause cervical cancer or genital warts. GBL uses AmpaSand beads technology to create identifiable clusters of beads that can be distinguished in a conventional flow cytometer. The company provides products to detect influenzaA, influenzaB, influenza A H1N1, influenzaA H5N1, respiratory syncytial virus, human metapneumovirus, adenovirus, rhinovirus, bordetella pertussis, and chlamydophila pneumonia. It collaborates with pathology customers and IVD companies. GBL is headquartered in Melbourne, Victoria, Australia. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Genera Biosystems Ltd
The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research  Development strategies
Develop marketentry and market expansion strategies
Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Related Biotechnology, Pharmaceutical and Healthcare News

Genera Biosystems Ltd GBI  Product Pipeline Analysis 2018 Update Report Updated 31102018 Prices from USD $750

Genera Biosystems Ltd GBI  Pharmaceuticals  Healthcare  Deals and Alliances Profile [Report Updated: 17092018] Prices from USD $250
13:26 EDT 15 Oct 2018 | BioPortfolio Reports
Summary
Genera Biosystems Ltd GBL is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is a molecular diagnostic test for the detection and genotyping of high risk and low risk types of human papillomavirus that cause cervical cancer or genital warts. GBL uses AmpaSand beads technology to create identifiable clusters of beads which can be distinguished in a conventional flow cytometer. The company provides products to detect influenzaA, influenzaB, influenza A H1N1, influenzaA H5N1, respiratory syncytial virus, human metapneumovirus, adenovirus, rhinovirus, bordetella pertussis, and chlamydophila pneumonia. It collaborates with pathology customers and IVD companies. GBL is headquartered in Melbourne, Victoria, Australia. Genera Biosystems Ltd GBI  Pharmaceuticals  Healthcare  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Genera Biosystems Ltd GBI  Pharmaceuticals  Healthcare  Deals and Alliances Profile Report Updated 17092018 Prices from USD $250

Genera Biosystems Ltd GBI  Medical Equipment  Deals and Alliances Profile [Report Updated: 16052018] Prices from USD $250
17:26 EDT 13 Aug 2018 | BioPortfolio Reports
Summary
Genera Biosystems Ltd GBL is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is a molecular diagnostic test for the detection and genotyping of high risk and low risk types of human papillomavirus that cause cervical cancer or genital warts. GBL uses AmpaSand beads technology to create identifiable clusters of beads which can be distinguished in a conventional flow cytometer. The company provides products to detect influenzaA, influenzaB, influenza A H1N1, influenzaA H5N1, respiratory syncytial virus, human metapneumovirus, adenovirus, rhinovirus, bordetella pertussis, and chlamydophila pneumonia. It collaborates with pathology customers and IVD companies. GBL is headquartered in Melbourne, Victoria, Australia. Genera Biosystems Ltd GBI  Medical Equipment  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Genera Biosystems Ltd GBI  Medical Equipment  Deals and Alliances Profile Report Updated 16052018 Prices from USD $250

Genera Biosystems Ltd GBI  Medical Equipment  Deals and Alliances Profile [Report Updated: 12072018] Prices from USD $250
20:53 EDT 6 Aug 2018 | BioPortfolio Reports
Summary
Genera Biosystems Ltd GBL is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is a molecular diagnostic test for the detection and genotyping of high risk and low risk types of human papillomavirus that cause cervical cancer or genital warts. GBL uses AmpaSand beads technology to create identifiable clusters of beads which can be distinguished in a conventional flow cytometer. The company provides products to detect influenzaA, influenzaB, influenza A H1N1, influenzaA H5N1, respiratory syncytial virus, human metapneumovirus, adenovirus, rhinovirus, bordetella pertussis, and chlamydophila pneumonia. It collaborates with pathology customers and IVD companies. GBL is headquartered in Melbourne, Victoria, Australia. Genera Biosystems Ltd GBI  Medical Equipment  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Genera Biosystems Ltd GBI  Medical Equipment  Deals and Alliances Profile Report Updated 12072018 Prices from USD $250

Beckman Coulter develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing. The company's diagnostic systems are found in hospitals and other critical care settings around the world, producing information used by physicians to diagnose diseases, make treatment decisions, and monitor patients. Scientists use the company's life science research instruments to study complex, biological problems, including causes of disease and potential new therapies or drugs. Beckman Coulter operates as a subsidiary of Danaher. The company was founded in 1935 and is based in Brea, California.

Beckman Coulter

The next stages of the partnership will involve integrating Genera Biosystems 's RTI-Plex and STI-Plex assays on the Beckman Coulter platform , as well as exploring expanding Genera Biosystems 's AmpaSand silica microspheres technology to work on the platform .

Genera teams up with Beckman Coulter, taps new CEO

Other Investors

Genera Biosystems is a development phase company that designs, develops and produces and clinically effective human molecular diagnostics with a focus on women's health.

Genera Biosystems

Queensland BioCapital Funds

Life Line Screening offers preventive health screening services for stroke, abdominal aortic aneurysm, peripheral arterial disease, diabetes, heart disease & osteoporosis.

MCM Solutions for Better Health is a provider of population health management programs that cover the entire continuum of care. It is a physician directed company that is URAC accredited and licensed in all states with requirements. The company was founded in 1986 and is based in Chicago, Illinois. On July 27th, 2022, MCM Solutions for Better Health was acquired by Valenz. The terms of the transaction were not disclosed.

Mike O’Connor

President

Save for later
NEW YORK – Helix Diagnostics has received Emergency Use Authorization from the US Food and Drug Administration for its multiplex SARS-CoV-2 test for serial testing, the FDA said on Monday. The Helix Diagnostics SARS nCoV-2019 Multiplexed Assay is a laboratory-developed test and is only authorized for use at the company's laboratory in Waterford, Michigan. The RT-PCR test detects SARS-CoV-2 RNA from anterior nasal swab samples that have either been collected by a healthcare provider or self-collected under the supervision of a healthcare provider when tested at least once per week, according to the EUA document. The FDA noted that the clinical performance of the test may vary depending on the circulating variants, including newly emerging strains of the virus, and their prevalence. It added that a study to determine the clinical performance of the test in people without symptoms or other reasons to suspect COVID-19 will be completed. The test received EUA under the umbrella EUA for serial testing, which allows authorized tests to be used with individual or pooled specimens to test people at least once per week regardless of symptoms or exposure to COVID-19, such as in serial testing programs implemented by schools or workplaces. Helix Diagnostics is not related to Helix, which also has multiple COVID-19 tests that have received FDA EUA.

Helix Diagnostics SARS-CoV-2 Test Nabs FDA EUA for Serial Testing

Palace Sports & Entertainment

Detroit Lions

Baltimore Ravens

Madison Square Garden Company

KPMG

Incubator/Accelerator

Helix Diagnostics LLC is pursuing development and commercialization of multiplexed DNA detection systems based on capillary electrophoresis.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare Genera Biosystems vs Helix Diagnostics

Customers evaluate the quality of Genera Biosystems's products using the following success metrics.